Current price is more than the intrinsic value

Intrinsic Value

Stock has been generating better return on equity than bank FD

ROE vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

Price behaviour puzzles analysts as ‘It defies any logic’

Why Dr Lal PathLabs’ November futures trade in deep discount?

Asian Paints Ltd, JSW Holdings Ltd, Intellect Design Arena Ltd and Dr Lal Pathlabs Ltd are among the other losers in the BSE’s ‘A’ group today, 29 September 2022.

Aarti Industries Ltd leads losers in ‘A’ group

Dr Lal PathLabs shares gained 1.7 percent to Rs 2,694.35, continuing uptrend for the seventh consecutive session. It has seen formation of bullish candle on the daily charts with higher high higher low formation for seven straight sessions, and has given a breakout of downward sloping resistance tre…

Trade Spotlight | What should you do with India Cements, Dr Lal PathLabs, Glenmark Pharma on Thursday?

Dr Lal Pathlabs में जानें निवेश को लेकर क्या है Experts की राय. जानें किन Levels पर करना चाहिए आपको खरीदारी और क्या है Target Price, देखें वीडियो. 
#cnbcawaazlive #drlalpathlabs #drlalpathlabssharenews #aajkatajakhabar  #businessnewslive  #stockmarketlive  #sharemarketlive 

cnbc awaaz live,cnbc awaaz live streaming,cnbc awaaz live hindi,cnbc awaaz,live cnbc awaaz,cnbc,cnbc live,stock market cnbc awaaz,final trade cnbc awwaz live,final trade cnbc bazaar,cnbc awaaz stock pick,cnbc final trade,cnbc awaaz share market,cnbc awaaz intraday picks,cnbc final trade live,cnbc awaaz budget 2022 live,stock market cnbc awaaz, cnbc awaaz live,cnbc,share bazaar live,n18oc_business


CNBC Awaaz is India’s number one business channel and an undisputed leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.

Subscribe to the CNBC Awaaz YouTube channel here: https://tinyurl.com/y5rsvesk

Follow CNBC Awaaz on Twitter: https://twitter.com/CNBC_Awaaz
Like us on our CNBC Awaaz Facebook page: https://www.facebook.com/cnbcawaaz
Website: https://bit.ly/3230WJW

Dr Lal Pathlabs Share News: 38% नीचे Stock, क्या खरीदारी करने की है सलाह? | Awaaz Special

Dr Lal Pathlabs में जानें निवेश को लेकर क्या हैै Experts की राय. जानें निवेश को लेकर क्या है Experts की राय. जानें किन levels पर करना चाहिए आपको खरीदारी और क्या है Target price, os

Share Market से जुड़ी हर छोटी या बड़ी खबर, चाहे हो Nifty में आए नए हाई या फिर, हो आपके के लिए स्टॉक्स पर राय, बिजनेस न्यूज हो या पॉलिटिकल न्यूज, कोरोनावायरस की न्यूज हो या फिर इलेक्शन, देखें CNBC Awaaz और रहे हर खबर से updated.

#CNBCAwaazLive #ShareMarketLive #StockMarketLiveUpdate #TopTradingIdeas #AajKaTajaKhabar #BusinessNewsLive #StockMarketLive #ShareMarketLive #stockmarketindia 



CNBC Awaaz is India’s number one business channel and an undisputed leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.

Subscribe to the CNBC Awaaz YouTube channel here: https://tinyurl.com/y5rsvesk

Follow CNBC Awaaz on Twitter: https://twitter.com/CNBC_Awaaz
Like us on our CNBC Awaaz Facebook page: https://www.facebook.com/cnbcawaaz
Website: https://bit.ly/3230WJW

Dr Lal Pathlabs Share News: Sell करने की क्यों है सलाह? | Kamai Ka Adda | CNBC Awaaz

Gurgaon-headquartered Dr Lal PathLabs and other diagnostic chains are feeling the heat due to the big drop in demand for Covid-19 testing, competition intensifying with the entry of e-pharmacies, web aggregators and pharma companies into diagnostics, resulting in a price war at a time when inflation…

Dr Lal pulls up its socks as competition mounts

Dr Lal PathLabs pulls up its socks as competition mounts

Diagnostic services provider Dr Lal Path Labs on Thursday said its consolidated net profit declined 57% to Rs 58 crore for the first quarter ended June 30. The company had reported a net profit of Rs 134 crore in the April-June period of the last fiscal. Revenue from operations declined to Rs 503 crore in the period under review from Rs 607 crore a year ago, Dr Lal PathLabs said in a regulatory filing. The company's board has also declared an interim dividend of Rs 6 per share for the current fiscal. Bharath Uppiliappan, CEO, Dr Lal PathLabs shares more details on ET NOW
Subscribe To ET Now For Latest Updates On Stocks, Business, Trading | ► https://goo.gl/SEjvK3

Subscribe Now To Our Network Channels :-
Times Now  : http://goo.gl/U9ibPb
The NewsHour Debate : http://goo.gl/LfNgFF

To Stay Updated Download the Times Now App :-
Android Google Play :  https://goo.gl/zJhWjC
Apple App Store :  https://goo.gl/d7QBQZ

Social Media Links :-
Twitter - http://goo.gl/hA0vDt
Facebook - http://goo.gl/5Lr4mC
G+ - http://goo.gl/hYxrmj
Website - www.etnownews.com

Non Covid Revenue Has Grown By 25% | Bharath Uppiliappan, Dr Lal PathLabs

On the firm’s Q1FY23 numbers, Om Manchanda said the diagnostics chain’s legacy business was up 15% YoY

We are focussed on productivity, says Dr Lal PathLabs MD

Diagnostic services provider Dr Lal Path Labs on Thursday said its consolidated net profit declined 57 per cent to Rs 58 crore for the first quarter ended June 30

Dr Lal PathLabs Q1 net profit dips 57% to Rs 58 cr; revenue falls 17%

Dr Lal PathLabs board has declared an interim dividend of ₹6 per share for the current fiscal

Dr Lal PathLabs Q1 net profit dips 57 per cent to ₹58 cr

Dr Lal Pathlabs Private Limited is headquartered in Gurgaon, Haryana, India and is a medical laboratory operator. 

Dr. Lal PathLabs Ltd

Dr. Lal PathLabs Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Why Dr Lal PathLabs’ November futures trade in deep discount?

Aarti Industries Ltd leads losers in ‘A’ group

Trade Spotlight | What should you do with India Cements, Dr Lal PathLabs, Glenmark Pharma on Thursday?

News Video

Dr Lal Pathlabs Share News: 38% नीचे Stock, क्या खरीदारी करने की है सलाह? | Awaaz Special

News Video

Dr Lal Pathlabs Share News: Sell करने की क्यों है सलाह? | Kamai Ka Adda | CNBC Awaaz

Dr Lal pulls up its socks as competition mounts

Dr Lal PathLabs pulls up its socks as competition mounts

Dr. Lal PathLabs Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Why Dr Lal PathLabs’ November futures trade in deep discount?

Aarti Industries Ltd leads losers in ‘A’ group

Trade Spotlight | What should you do with India Cements, Dr Lal PathLabs, Glenmark Pharma on Thursday?

News Video

Dr Lal Pathlabs Share News: 38% नीचे Stock, क्या खरीदारी करने की है सलाह? | Awaaz Special

News Video

Dr Lal Pathlabs Share News: Sell करने की क्यों है सलाह? | Kamai Ka Adda | CNBC Awaaz

Dr Lal pulls up its socks as competition mounts

Dr Lal PathLabs pulls up its socks as competition mounts

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock